Governments have consistently approached change as a coordinated exercise, bundling multiple elements into single negotiations rather than adjusting one lever at a time. This pattern has shaped outcomes across pricing, pharmacy agreements, and the evolution of both off-patent and innovative medicine sectors, and it continues to define how the next phase of reform is likely to unfold.
Those who recognise and respond to the reality will be better positioned to shape reforms
March 31, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Pharmac announces plan to revise it recently expanded patient advisory function
August 4, 2026 - - Latest News -
Australian company announces agreement with Lilly to trial lung cancer combination
August 4, 2026 - - Latest News -
This complete absence of patient power and agency makes this a health system outlier
August 4, 2026 - - Latest News -
Arrotex Pharmaceuticals appoints experienced industry executive as CMO
August 4, 2026 - - Latest News -
The risk to patients is that new pricing policies could swamp any benefit from the HTA Review
August 4, 2026 - - Latest News -
Potential merger could create a new global oncology powerhouse
August 3, 2026 - - Latest News -
The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants
August 3, 2026 - - Latest News

